Canine Osteosarcoma Cell Line (OSCA-32) from KERAFAST, INC.

Search, find, compare suppliers for Canine Osteosarcoma Cell Line (OSCA-32) products.

Edit 
Product NameCanine Osteosarcoma Cell Line (OSCA-32)
DescriptionSource: Bone (radius). Cell type: Osteosarcoma.
Size1 vial
Concentrationn/a
Applicationsn/a
Other Namesn/a
Gene, Accession, CAS #n/a
Catalog #EMN002-FP
Price$605
Order / More InfoCanine Osteosarcoma Cell Line (OSCA-32) from KERAFAST, INC.
Product Specific References
  1. Scott MC, Sarver AL, Gavin KJ, Thayanithy V, Getzy DM, Newman RA, Cutter GR, Lindblad-Toh K, Kisseberth WC, Hunter LE, Subramanian S, Breen M, Modiano JF. Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. Bone. 2011 Sep;49(3):356-67. doi: 10.1016/j.bone.2011.05.008. Epub 2011 May 15.
  2. Modiano JF, Bellgrau D, Cutter GR, Lana SE, Ehrhart NP, Ehrhart E, Wilke VL, Charles JB, Munson S, Scott MC, Pozniak J, Carlson CS, Schaack J, Duke RC. Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. Mol Ther. 2012 Dec;20(12):2234-43. doi: 10.1038/mt.2012.149. Epub 2012 Jul 31.
  3. Cannon CM, Pozniak J, Scott MC, Ito D, Gorden BH, Graef AJ, Modiano JF. Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors. Vet Comp Oncol. 2015 Mar;13(1):48-59. doi: 10.1111/vco.12018. Epub 2013 Feb 15.
  4. Murahari S, Jalkanen AL, Kulp SK, Chen CS, Modiano JF, London CA, KisseberthWC. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.BMC Cancer. 2017 Jan 21;17(1):67. doi: 10.1186/s12885-017-3046-6. PubMed PMID:28109246; PubMed Central PMCID: PMC5251323.
  5. Scott MC, Tomiyasu H, Garbe JR, Cornax I, Amaya C, O'Sullivan MG, Subramanian S, Bryan BA, Modiano JF. Heterotypic mouse models of canine osteosarcomarecapitulate tumor heterogeneity and biological behavior. Dis Model Mech. 2016Dec 1;9(12):1435-1444. Epub 2016 Nov 3. PubMed PMID: 27874835; PubMed CentralPMCID: PMC5200896.
  6. Fenger JM, Roberts RD, Iwenofu OH, Bear MD, Zhang X, Couto JI, Modiano JF,Kisseberth WC, London CA. MiR-9 is overexpressed in spontaneous canineosteosarcoma and promotes a metastatic phenotype including invasion and migrationin osteoblasts and osteosarcoma cell lines. BMC Cancer. 2016 Oct 10;16(1):784.PubMed PMID: 27724924; PubMed Central PMCID: PMC5057229.
  7. Scott MC, Sarver AL, Tomiyasu H, Cornax I, Van Etten J, Varshney J, O'SullivanMG, Subramanian S, Modiano JF. Aberrant Retinoblastoma (RB)-E2F TranscriptionalRegulation Defines Molecular Phenotypes of Osteosarcoma. J Biol Chem. 2015 Nov20;290(47):28070-83. doi: 10.1074/jbc.M115.679696. Epub 2015 Sep 16. PubMed PMID:26378234; PubMed Central PMCID: PMC4653667.
  8. Im KS, Graef AJ, Breen M, Lindblad-Toh K, Modiano JF, Kim JH. Interactionsbetween CXCR4 and CXCL12 promote cell migration and invasion of caninehemangiosarcoma. Vet Comp Oncol. 2017 Jun;15(2):315-327. doi: 10.1111/vco.12165. Epub 2015 Sep 3. PubMed PMID: 26337509.
  9. Lin W, Modiano JF, Ito D. Stage-specific embryonic antigen: determiningexpression in canine glioblastoma, melanoma, and mammary cancer cells. J Vet Sci.2017 Mar 30;18(1):101-104. doi: 10.4142/jvs.2017.18.1.101. PubMed PMID: 27456773;PubMed Central PMCID: PMC5366293.
KERAFAST, INC.
KERAFAST, INC.
KERAFAST, INC.
An Absolute Biotech Company
2 Shaker Road, Unit B101
Shirley MA 01464
P: +1-617-336-3228
P: +1-800-546-1760
F: +1-866-727-9826

info@kerafast.com
Tech Support: TechnicalSupport@kerafast.com

https://www.kerafast.com

Profile of KERAFAST, INC.

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.